- Nov 11, 2019
Remdesivir (GS-5734) produces a main metabolite GS-441524 which is also another Gilead drug developed around the same time in 2009. GS-441524 is less toxic than remdesivir (GS-5734)Does anyone know how remdesivir was designed, or if it was? Was it by knowledge of the viral enzyme's structure that was different from the various human polymerase active sites?
It is quite remarkable to deliver an adenosine nucleoside analog that gets converted to a triphosphate inactivating agent specific to the viral mechanism, and shuts it down. Avoiding an impact on similar mechanisms in the host is particularly remarkable. Perhaps it was developed by combinatorial chemistry, assuming that is still alive and well.
How bizzare!! what a load of rubbish theres no evidence at all!!! If the answer was yes it would be all over the news internationally & everyone would want a supplyTwo experimental drugs for feline coronavirus could show promise against COVID-19.
Could cat drugs treat humans with COVID-19? : Read more
How bizzare!! what a load of rubbish theres no evidence at all!!! If the answer was yes it would be all over the news internationally & everyone would want a supply
Two experimental drugs for feline coronavirus could show promise against COVID-19.
Could cat drugs treat humans with COVID-19? : Read more
My apologies -with respect despite what has been confirmed in writing over there -if it becomes a reality in the UK then I probably would carefully consider believing it .With respect I stick to my statement of opinion -apologies againThe FDA had confirmed in writing that they will now urgently investigate the drug GS-441524 as a Covid-19 treatment
See the Public Citizen link below for links to the pdfs of the open letters to and from the FDA and Gilead about this. No explaination was provided about why no research had been done to date
See also previous posts on GS-441524 in live science with links to the current research and previous clinical trials, animal tests and unofficial use which have then been blocked by Gilead from being applied despite a near 100% cure rate for a 100% fatal cat coronavirus
WASHINGTON, D.C. – The National Institutes of Health (NIH) will expeditiously conduct preclinical studies of GS-441524 as a treatment for COVID-19 and will make the results readily available to the scientific community, as requested in a letter sent to the agency by Public Citizen.
On Aug. 4, Public Citizen and two university-based drug researchers urged Gilead Sciences, Inc. and several government agencies, including the NIH, to advance development of GS-441524 as a potential treatment for COVID-19, because evidence shows it may offer significant advantages over the closely related antiviral drug remdesivir.
......director of the NIH’s National Center for Advancing Translational Sciences, Dr. Christopher Austin, on Aug. 22, stating that “Scientists in our Division of Preclinical Innovation have reviewed the literature and agree that [GS-441524] merits further exploration,” and that NIH scientists will quickly conduct preclinical studies of the drug.
“Public Citizen applauds the NIH’s commitment to conducting the necessary preclinical studies of GS-441524 as a potential treatment for COVID-19, and we await those results with great anticipation,” said Michael Abrams, health researcher at Public Citizen and lead author of the letter. “Such further study of the drug is long overdue, especially given the evidence that GS-441524 may be cheaper and easier to manufacture and more amenable to administration in inhaled or oral forms than remdesivir.”
NIH Agrees With Public Citizen, Will Conduct Preclinical Trials of the Potential COVID-19 Treatment GS-441524 - Public CitizenWASHINGTON, D.C. – The National Institutes of Health (NIH) will expeditiously conduct preclinical studies of GS-441524 as a treatment for…www.citizen.org
Gilead and the University of California jointly own the patent of GS-441524 the fatal cat corona virus cure also effective against coronaviruses SARS and MERS
Gilead currently holds 100% of the patent for Remdesivir the FDA approved treatment for Covid-19
Gilead has blocked the use of GS-441524 and failed to co-operate with University researchers looking at GS-441524 as a Covid-19 treatment, even though it is the only effective cure for the fatal cat corona virus FIP as shown by clinical trials carried out at the University of California, and is also effective against MERS and SARS
There is a good background article below and there is extensive medical research linked in the links at the end
Previous posts and links to news and medical research
Question - Please explain why Anivive's GC376 has been fast tracked over Gilead's GS-441524 for Covid-19 clinical trials ?A drug labelled GC376 owned by a company called Anivive has already been lab tested in Canada in 2020 in 2 months and promoted for Covid-19 clinical trials and human use partly on the basis it was shown some years ago as effective against a 100% fatal cat coronavirus FIP and tested on cats. It...forums.livescience.com
Coronavirus - GS-441524 a promising Covid-19 Treatment stalled - will Gilead and the FDA help Texas University cancer researchers find out the truth ?In May 2020 Cancer researchers from the University of Texas set out in some detail why Gileads drug GS-441524 was superior to Gileads Remdesivir as a Coronavirus treatment. This was based both on animals trials and previous research on GS-441524. In some animals trials GS-441524 was compared...forums.livescience.com
No need to apologize - everyone is free to make thier own decisions - however the "cat drug" is already effectively in the UK via Gileads drug remdesivir.My apologies -with respect despite what has been confirmed in writing over there -if it becomes a reality in the UK then I probably would carefully consider believing it .With respect I stick to my statement of opinion -apologies again
...Perhaps it was developed by combinatorial chemistry, assuming that is still alive and well.